Ethylene Glycol

Ethylene Glycol

SCHEMBL629180

NS(=O)(=O)CCS(N)(=O)=O.OCCO

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 14/20 0.38
CA1 P00915 6/20 0.38
CA9 Q16790 6/20 0.38
CA5A P35218 5/20 0.38
CA7 P43166 5/20 0.38
CA5B Q9Y2D0 5/20 0.38
CA4 P22748 4/20 0.38
CA6 P23280 4/20 0.38
TSHR P16473 2/20 0.38
NT5E P21589 1/20 0.38
CA12 O43570 3/20 0.36
CA14 Q9ULX7 2/20 0.36
CA3 P07451 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
LMNA P02545 1/20 0.33
SLC6A6 P31641 1/20 0.33
CYP2C19 P33261 1/20 0.33
BLM P54132 1/20 0.33
RECQL P46063 1/20 0.32
APP P05067 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL160212 0.86
SCHEMBL1644673 0.84 CA2 (0.46) CA2CA1CA9CA5ACA7
Sulfamide SCHEMBL27475146 0.81 CA2 (0.55) CA2CA1CA9CA5ACA7
Sulfamide SCHEMBL27491894 0.81
SCHEMBL1804507 0.80
SCHEMBL1805054 0.78
SCHEMBL10622461 0.76 LMNA (0.53) CA2CA1CA9CA5ACA7
SCHEMBL1869757 0.76 CA2 (0.47) CA2TSHRLMNA
SCHEMBL9952155 0.76 CA2 (0.47) CA2TSHRLMNA
SCHEMBL1164487 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268634-A2 PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES Actavis Group PTC EHF (IS) 2011-01-05 EP claimed
WO-2009112954-A2 PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2009-09-17 WO claimed
EP-1254121-B1 PREPARATION OF SULFONAMIDES HOFFMANN LA ROCHE (CH) 2006-02-01 EP claimed
CN-1178921-C Preparation of sulfonamides - 2004-12-08 CN claimed
CN-1425007-A Preparation of sulfonamides HOFFMANN LA ROCHE (CH) 2003-06-18 CN claimed
EP-1254121-A1 PREPARATION OF SULFONAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2002-11-06 EP claimed
WO-2001055120-A1 PREPARATION OF SULFONAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2001-08-02 WO claimed
US-6136971-A Preparation of sulfonamides ROCHE COLORADO CORPORATION (US) 2000-10-24 US claimed
CN-114907275-A Preparation method of bosentan 武汉工程大学 2022-08-16 CN disclosed
EP-2245018-B1 PROCESS FOR PREPARING BOSENTAN GENERICS UK LTD (GB) 2017-08-30 EP disclosed
EP-2738165-B1 Method by means of phase transfer catalysis WÖRWAG PHARMA GMBH & CO KG (DE) 2016-10-12 EP disclosed
US-9296705-B2 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2(2-pyrimidinyl)-pyrimidine-4-yl)-benzen esulfonamide sodium DAVULURI RAMAMOHAN RAO (IN) 2016-03-29 US disclosed
US-20150232430-A1 4-TERT-BUTYL-N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(2-PYRIMIDINYL)-PYRIMIDINE-4-YL)-BENZEN ESULFONAMIDE SODIUM Rao, Davuluri Ramamohan (IN) 2015-08-20 US disclosed
EP-2550256-B1 PROCESS FOR THE PREPARATION OF BOSENTAN LESVI LABORATORIOS SL (ES) 2015-07-15 EP disclosed
CN-1178921-C Preparation of sulfonamides - 2004-12-08 CN disclosed
CN-1523084-A Additive for improving fuel lubricating property and application thereof 中国石油天然气股份有限公司 2004-08-25 CN disclosed
CN-1425007-A Preparation of sulfonamides HOFFMANN LA ROCHE (CH) 2003-06-18 CN disclosed
EP-1254121-A1 PREPARATION OF SULFONAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2002-11-06 EP disclosed
WO-2001055120-A1 PREPARATION OF SULFONAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2001-08-02 WO disclosed
US-6136971-A Preparation of sulfonamides ROCHE COLORADO CORPORATION (US) 2000-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232430-A1 4-TERT-BUTYL-N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(2-PYRIMIDINYL)-PYRIMIDINE-4-YL)-BENZEN ESULFONAMIDE SODIUM EDNRB, ECE2, EDNRA CA2 1862/4885CA1 4866/4885CA9 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.